sorafenib has been researched along with naphthalimides in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (naphthalimides) | Trials (naphthalimides) | Recent Studies (post-2010) (naphthalimides) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,045 | 48 | 738 |
| Protein | Taxonomy | sorafenib (IC50) | naphthalimides (IC50) |
|---|---|---|---|
| Chain A, Cholix toxin | Vibrio cholerae | 0.411 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 1.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appella, D; Avram, MJ; Chen, Z; Green, R; Gupta, P; Huang, M; Huang, S; Kandela, I; Liu, Y; Lou, G; Mazar, A; Norton, JT; Shank, NI; Tang, S; Wang, C | 1 |
1 other study(ies) available for sorafenib and naphthalimides
| Article | Year |
|---|---|
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Naphthalimides; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |